Human exposures and their associated hearing loss profiles: Music industry professionals

Wartinger, Frank; Malyuk, Heather; Portnuff, Cory

doi:10.1121/1.5132541

Cited by 15 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…administration of the therapeutic agent. It is reasonable to infer that many of the individuals at risk for NIHL, such as Service members, 37 124 employees working in loud industries, 40 musicians and other performing artists, 38 and others who are exposed to loud recreational sound 125 126 would find an oral therapeutic easier to administer on a regular basis given recurring sound exposure, which may explain the bias towards oral therapeutics in NIHL otoprotection clinical trials.…”

Section: Resultsmentioning

confidence: 99%

“…A variety of review papers highlight the diverse clinical trial paradigms used in NIHL otoprotection that have emerged over time, with widely varying participant noise exposure 32 and diverse study outcomes to be considered. [33][34][35][36] The problem of NIHL and difficulties accessing populations in which human NIHL otoprotection or treatment can be both reliably and ethically investigated has been a topic of recent discussion for Service members, 37 musicians and other performing artists, 38 and workers exposed to occupational noise. 39,40 Within human DIHL research, recent detailed reviews have addressed clinical trials listed in ClinicalTrials.gov 17,41 and strategies for measuring DIHL.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Prell

2021

J Am Acad Audiol

View full text Add to dashboard Cite

Background The previous 30 years have provided information on the mechanisms of cell death in the inner ear after noise exposure, ototoxic drug injury, and during aging, and clinical trials have emerged for all of these acquired forms of hearing loss. Sudden hearing loss is less well understood, but restoration of hearing after sudden hearing loss is also a long-standing drug target, typically using steroids as an intervention but with other agents of interest as well. Purpose The purpose of this review was to describe the state of the science regarding clinical testing of investigational medicinal products for the inner ear with respect to treatment or prevention of acquired hearing loss. Data Collection and Analysis Comprehensive search and summary of clinical trials listed in the National Library of Medicine (www.ClinicalTrials.gov) database identified 61 clinical trials. Results Study phase, status, intervention, and primary, secondary, and other outcomes are summarized for studies assessing prevention of noise-induced hearing loss, prevention of drug-induced hearing loss, treatment of stable sensorineural hearing loss, and treatment of sudden sensorineural hearing loss. Conclusion This review provides a comprehensive summary of the state of the science with respect to investigational medicinal products for the inner ear evaluated in human clinical trials, and the current challenges for the field.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Prell

2021

J Am Acad Audiol

View full text Add to dashboard Cite

show abstract

“…Despite the above limitations, EHF hearing is considered particularly important for musicians and other performing artists (191), with monitoring of EHF thresholds recommended for monitoring hearing loss in these populations (4). Thus, even though the inclusion of this metric has not been common in studies to date, clinical trials that selectively recruit participants who rely on EHF thresholds should consider measuring EHF thresholds as a secondary or other outcome as previously discussed by others (15,93,98,105).…”

Section: Ehf Audiometry As Clinical Trial Outcomesmentioning

confidence: 99%

“…Noise-induced hearing loss (NIHL) is a significant clinical issue. It is well known to impact those who work in loud occupational settings (76,77,178,179), members of the armed forces (41,56,196), and musicians and other performing artists (67,181,191).…”

Section: Introductionmentioning

confidence: 99%

Prevention of Noise-Induced Hearing Loss Using Investigational Medicines for the Inner Ear: Previous Trial Outcomes Should Inform Future Trial Design

Prell

2022

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

Significance. Noise-induced hearing loss (NIHL) is an important public health issue resulting in decreased quality of life for affected individuals and significant costs to employers and governmental agencies.Recent Advances. Advances in the mechanistic understanding of NIHL have prompted a growing number of proposed, in-progress, and completed clinical trials for possible protections against NIHL via antioxidants and other drug agents. Thirty-one clinical trials evaluating prevention of either temporary or permanent NIHL were identified and are reviewed.Critical Issues. This review revealed little consistency in the noise-exposed populations in which drugs are evaluated or the primary outcomes used to measure NIHL prevention.Changes in pure-tone thresholds were the most common primary outcome; specific threshold metrics included both average hearing loss and incidence of significant hearing loss. Changes in otoacoustic emission (OAE) amplitude were a relatively common secondary outcome. Extended high frequency (EHF) hearing and speech-in-noise perception are commonly adversely affected by noise exposure but are not consistently included in clinical trials assessing prevention of NIHL.Future Directions. Multiple criteria are available for monitoring NIHL, but the specific criterion to be used to define clinically significant otoprotection remains a topic of discussion. Audiogram-based primary outcome measures can be combined with secondary outcomes, including OAE amplitude, EHF hearing, speech-in-noise testing, tinnitus surveys, and patient-reported outcomes. Standardization of test protocols for the above primary and secondary outcomes, and associated reporting criterion for each, would facilitate clinical trial design and comparison of results across investigational drug agents.

show abstract

“…B. einer Schwerhörigkeit oder Tinnitus, ist bei PEU das Wissen um deren berufliche Tätigkeit ebenfalls zentral. So wirkt eine Schwerhörigkeit bei PEU stark stigmatisierend und stellt bei einer eventuellen Hörgeräteversorgung spezielle Herausforderungen an den Hörgeräteakustiker [17,113].…”

Section: üBersichten Hintergrundunclassified

Der „Professional Ear User“ – Implikationen für die Prävention, Diagnostik und Therapie von Ohrerkrankungen

Bächinger

Raphael

Hannig

et al. 2022

HNO

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Ein vollständig intaktes Hörvermögen ist zentral für die Ausübung verschiedener Berufe wie Instrumentenbaumeister, Musiker, Tonmeister sowie für weitere Berufsgruppen ohne Bezug zu Musik wie beispielsweise Sonar-Techniker. Für Personen all dieser Berufsgruppen schlagen wir in Analogie zum „Professional Voice User“ den Begriff „Professional Ear User“ (PEU) vor. PEU haben spezielle Anforderungen an ihre Ohrgesundheit, da sie über eine überdurchschnittliche auditive Wahrnehmungsfähigkeit verfügen, von der sie beruflich abhängig sind. Fragestellung Die vorliegende narrative Übersichtsarbeit hat zum Ziel, die sich daraus ergebenden speziellen Aspekte der Prävention, Diagnostik und Therapie von Ohrerkrankungen bei PEU zusammenzufassen. Ergebnisse und Schlussfolgerung Die Prävention von Hörstörungen und weiteren Ohrerkrankungen umfasst den Schutz vor zu hohen Schallpegeln, die Vermeidung von Ototoxinen oder Nikotin sowie die korrekte Durchführung einer Gehörgangsreinigung. Die Abklärung von Hörstörungen kann sich bei PEU herausfordernd gestalten, da subklinische, jedoch einschränkende Veränderungen des Hörvermögens mit konventionellen audiometrischen Methoden nicht zuverlässig objektiviert werden können. Schließlich kann das Vorliegen einer Ohrerkrankung bei einem PEU Therapieentscheidungen beeinflussen. Weiter muss bei PEU auch eine hohe Wachsamkeit bezüglich nichtorganischer Ohrerkrankungen bestehen. Abschließend werden Möglichkeiten diskutiert, um bei PEU eine umfassende Ohrgesundheit im Rahmen eines edukativen Programms zu fördern und mittels einer spezialisierten ohrenärztlichen Sprechstunde zu erhalten. Im Gegensatz zu bestehenden Konzepten ist der Fokus dabei auf die Gesamtheit der Berufsgruppen gerichtet, welche in professionellem Rahmen speziell von der Ohrgesundheit abhängig sind. Außerdem soll der Schwerpunkt hierbei nicht nur auf Hörstörungen und deren Prävention, sondern auch auf der Erhaltung einer ganzheitlichen Ohrgesundheit liegen.

show abstract

Human exposures and their associated hearing loss profiles: Music industry professionals

Cited by 15 publications

References 36 publications

Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov

Prevention of Noise-Induced Hearing Loss Using Investigational Medicines for the Inner Ear: Previous Trial Outcomes Should Inform Future Trial Design

Der „Professional Ear User“ – Implikationen für die Prävention, Diagnostik und Therapie von Ohrerkrankungen

Contact Info

Product

Resources

About